Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 29, 2026
Key Takeaways
- Record FDA approval pace: The U. [Source: U.S. Food and Drug Administration]S. Food and Drug Administration (FDA) approved 18 biosimilars in both 2024 and 2025 (through Q3), totaling 76 approvals to date and representing a 260% increase from 5 approvals in 2023.
- Therapeutic concentration: Biosimilar approvals are concentrated in oncology, immunology, and ophthalmology, targeting high-value reference biologics including adalimumab (Humira), denosumab (Prolia/Xgeva), and ustekinumab (Stelara).
- Market access expansion: Accelerated FDA biosimilar approvals are increasing lower-cost treatment alternatives, potentially reducing patient out-of-pocket costs and improving access across major therapeutic categories.
- Competitive implications: The surge in FDA monoclonal antibody approval activity signals intensifying price competition and market share pressure for originator biologics, reshaping the competitive landscape for established manufacturers.
The U.S. biosimilars market is experiencing unprecedented regulatory momentum, with the FDA approving a record 18 biosimilars in 2024 and maintaining that pace through the third quarter of 2025, bringing cumulative approvals to 76. This acceleration—a 260% increase from just 5 approvals in 2023—reflects the FDA's commitment to expediting market entry for lower-cost monoclonal antibody alternatives in oncology, immunology, and ophthalmology. Why it matters: The rapid expansion of FDA biosimilar approvals directly addresses healthcare cost pressures while increasing treatment options for millions of patients relying on expensive reference biologics.
FDA Biosimilar Approval Trends: Accelerated Regulatory Activity
The FDA's biosimilar approval trajectory has shifted dramatically over the past three years. In 2023, the agency approved 5 biosimilars. This number surged to 18 approvals in 2024, and the pace has remained consistent through the third quarter of 2025 with an additional 18 approvals, bringing the total biosimilar portfolio to 76 FDA-approved products to date.
This acceleration reflects the maturation of the FDA's 351(k) regulatory pathway under the Biologics Price Competition and Innovation (BPCIA) Act of 2009, which established an abbreviated approval mechanism for biosimilars. The FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have refined their scientific review frameworks, enabling faster turnaround times while maintaining rigorous comparability standards for analytical, animal, and clinical data.
The regulatory momentum also signals the FDA's strategic alignment with the Biden-Harris administration's healthcare affordability agenda, which has prioritized biosimilar market development as a mechanism to reduce drug spending. Compared with the European Medicines Agency's (EMA) longer history with biosimilars—which has resulted in over 80 approved products since 2006—the U.S. approval rate now represents a meaningful catch-up, though the absolute number of available biosimilars in clinical practice remains lower due to market adoption barriers.
What to watch next: Continued FDA approval acceleration is expected as the agency processes a robust pipeline of pending biosimilar applications, with particular focus on high-value reference biologics with expiring patent protections.
Key Therapeutic Areas and Target Reference Products
The 76 FDA-approved biosimilars are concentrated in three therapeutic domains that represent the highest clinical and economic value in the biologic market.
Oncology: This therapeutic area remains the largest target for biosimilar development. Monoclonal antibody biosimilars targeting reference products used in solid tumors and hematologic malignancies have accounted for a substantial portion of recent FDA approvals. These include biosimilars of key checkpoint inhibitors and targeted therapy agents that drive significant healthcare spending in cancer treatment.
Immunology: Biosimilars of adalimumab (Humira) represent a landmark development in this category. Adalimumab, a TNF-alpha inhibitor used in rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other autoimmune conditions, has been one of the world's best-selling drugs, with U.S. sales historically exceeding $16 billion annually. The approval of multiple adalimumab biosimilars has begun fragmenting this market, introducing significant price competition. Additionally, biosimilars of ustekinumab (Stelara), an IL-12/23 inhibitor for psoriasis and inflammatory bowel disease, have entered the market, further diversifying immunology treatment options.
Ophthalmology: Biosimilars targeting reference products for age-related macular degeneration and other retinal conditions have expanded ophthalmology's biosimilar portfolio. These approvals address a therapeutic area with significant unmet needs and growing patient populations.
A third key reference biologic, denosumab (Prolia/Xgeva), a RANKL inhibitor used in osteoporosis and cancer-related bone disease, has also become a target for biosimilar manufacturers. The approval of denosumab biosimilars expands access to bone-protective therapies across multiple indications, addressing a large patient population in both oncology and endocrinology.
The concentration of approvals in these three areas reflects both market opportunity and scientific feasibility. These reference biologics represent blockbuster products with substantial patient populations, creating strong commercial incentives for biosimilar development. Simultaneously, the established regulatory pathways and comparative data requirements for these therapeutic classes have enabled sponsors to navigate the approval process more efficiently.
Biosimilar Pricing Strategies and Market Penetration Dynamics
Biosimilar pricing in the U.S. market has emerged as a critical competitive lever, though dynamics differ substantially from European markets. In the European Union, biosimilar prices typically launch at 20-40% discounts to reference biologics, with deeper discounts materializing as multiple biosimilars enter the market. U.S. pricing has followed a similar trajectory but with notable variations driven by payer dynamics and the absence of a centralized pricing authority.
Adalimumab biosimilars have demonstrated this pricing pressure acutely. Upon entry of the first adalimumab biosimilar in 2023, reference product pricing declined modestly, with greater discounts emerging as additional biosimilars achieved FDA approval. This competitive dynamic is expected to intensify as the biosimilar portfolio expands, creating cumulative pricing pressure on originator manufacturers.
Market penetration, however, remains constrained by several factors distinct from the clinical approval landscape. First, payer acceptance and formulary positioning require negotiation between biosimilar manufacturers and pharmacy benefit managers (PBMs), health plans, and integrated delivery systems. Second, physician prescribing habits and familiarity with reference products create clinical inertia, particularly in specialty care settings where switching costs—both perceived and actual—may be high. Third, the FDA's interchangeability designation, which permits pharmacist-level substitution without physician authorization, has been granted to only a subset of approved biosimilars, limiting automatic market capture.
The competitive landscape for originator manufacturers has shifted accordingly. Reference product manufacturers have employed several strategic responses: implementing patient assistance programs to reduce out-of-pocket costs, pursuing label expansions to extend patent exclusivity, and investing in combination therapies that may retain market share even as monotherapy competition intensifies. Some originators have also launched authorized generic versions of their reference biologics—biosimilars manufactured by the originator under a different brand—to capture market share before competitors gain significant traction.
Regulatory Context: FDA Pathway and Policy Framework
All 76 FDA-approved biosimilars have navigated the 351(k) pathway established under the BPCIA. This abbreviated approval mechanism requires demonstration of biosimilarity to a reference product through a stepwise analytical, preclinical, and clinical comparative assessment. Unlike the traditional Biologic License Application (BLA) pathway for novel biologics, the 351(k) pathway does not require separate efficacy and safety trials in each indication; instead, sponsors may rely on comparative clinical immunogenicity and pharmacology data in a single indication, with extrapolation to other indications supported by mechanism of action, pharmacokinetics, and pharmacodynamics data.
The FDA has published detailed guidance documents—including the 2015 "Scientific Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product" guidance and subsequent disease-specific guidance—that have clarified expectations for analytical comparability, animal study design, and clinical trial endpoints. This regulatory clarity has reduced uncertainty and shortened development timelines relative to the early biosimilar approvals in 2015-2018, when precedent was limited.
No special designations such as Breakthrough Therapy Designation (BTD) or Priority Review have been systematically applied to biosimilar applications, as these designations are reserved for novel therapeutics addressing unmet medical needs. Biosimilars, by definition, do not represent novel therapeutic entities and therefore do not qualify for these expedited pathways. However, the FDA has maintained standard or priority review timelines (10 or 6 months, respectively) for biosimilar applications, depending on the completeness of submission and review complexity.
Market Impact: Competitive Positioning and Patient Access
The influx of FDA biosimilar approvals is reshaping competitive dynamics across oncology, immunology, and ophthalmology. For originator manufacturers, the entry of biosimilars represents a significant erosion of monopoly pricing power, particularly as reference product patents expire and regulatory exclusivity periods conclude. The adalimumab market provides a case study: once patent protection ended in late 2023, multiple biosimilar approvals followed rapidly, fragmenting a market that had generated peak annual U.S. sales exceeding $16 billion for a single originator.
For payers and patients, biosimilar approvals create opportunities for cost mitigation. Biosimilars typically launch at 15-30% discounts to reference products, with deeper discounts negotiated as competitive intensity increases. For self-insured employers and Medicare beneficiaries, these price reductions translate to lower premiums and out-of-pocket costs. For uninsured or underinsured patients, biosimilar availability may improve access by reducing treatment barriers.
The patient population benefiting from biosimilar expansion is substantial. Adalimumab alone is prescribed to approximately 2 million U.S. patients annually across multiple indications. Denosumab serves a similarly large population in osteoporosis and cancer-related bone disease. Ustekinumab reaches hundreds of thousands of patients with psoriasis and inflammatory bowel disease. As biosimilars penetrate these markets, cumulative savings across the healthcare system could reach billions of dollars annually, though exact figures depend on adoption rates and payer policies.
Competitive positioning among biosimilar manufacturers themselves is also intensifying. Sponsors with earlier FDA approvals and established payer relationships have first-mover advantages in market share capture. Conversely, later entrants must differentiate through pricing, supply chain reliability, patient support programs, or clinical data demonstrating advantages in specific patient subpopulations—though the latter approach risks regulatory scrutiny and requires robust evidence.
Future Outlook: Opportunities and Challenges in the U.S. Biosimilars Market
The FDA biosimilar approval pipeline remains robust, with multiple applications pending for high-value reference biologics. The continuation of 18+ annual approvals is anticipated through 2026 and beyond, contingent on sponsor submission activity and FDA review capacity. Key reference products with near-term patent expirations and significant commercial value are likely to attract multiple biosimilar applications, further accelerating market fragmentation in oncology and immunology.
Evolving regulatory policies may further accelerate biosimilar adoption. The FDA has signaled interest in streamlining the 351(k) pathway for certain well-characterized drug classes, potentially reducing development timelines and lowering barriers to entry for smaller manufacturers. Additionally, Centers for Medicare & Medicaid Services (CMS) policies governing biosimilar reimbursement and the granting of interchangeability status could significantly influence market penetration rates.
Opportunities for cost savings and improved patient access are substantial but not guaranteed. Realizing these benefits requires coordinated action among regulators, payers, manufacturers, and clinicians to address market adoption barriers. Payer education regarding biosimilar efficacy and safety parity with reference products remains critical, as lingering clinical skepticism continues to impede formulary placement and prescribing.
Challenges persist on multiple fronts. Patent litigation between originator and biosimilar manufacturers continues to delay market entry in certain cases, with disputes centering on patent scope, obviousness, and secondary patent strategies employed by originators. The interchangeability designation process, while intended to facilitate automatic substitution, has been granted conservatively by the FDA, limiting the competitive advantage of biosimilar manufacturers. Market education—both among healthcare providers and patients—remains incomplete, with concerns about biosimilar efficacy and safety still prevalent despite extensive clinical data supporting equivalence.
Additionally, supply chain resilience for biosimilar manufacturing may become a competitive factor as multiple manufacturers scale production. Manufacturing capacity constraints, particularly for complex monoclonal antibodies, could limit market penetration if demand outpaces supply. Conversely, overcapacity in biosimilar manufacturing could drive further price compression, intensifying margin pressure across the industry.
Frequently Asked Questions
What is a biosimilar, and how does it differ from a generic drug?
A biosimilar is a biologic product that is highly similar to an FDA-approved reference biologic product, with no clinically meaningful differences in safety, purity, or potency. Biosimilars are manufactured using living cells or organisms and require comparative analytical, animal, and clinical data to demonstrate biosimilarity. Generic drugs, by contrast, are chemically synthesized small-molecule copies of reference drugs that can be approved through abbreviated pathways (ANDA) without comparative clinical trials, as chemical identity ensures bioequivalence. Biologics, including monoclonal antibodies, are too complex to be copied exactly; hence, biosimilars represent a different regulatory and clinical category.
What does the FDA 351(k) pathway require for biosimilar approval?
The FDA 351(k) pathway, established under the BPCIA, requires a stepwise demonstration of biosimilarity through: (1) analytical studies comparing structural and functional characteristics of the proposed biosimilar and reference product; (2) animal toxicity studies; (3) clinical pharmacology studies assessing pharmacokinetics and pharmacodynamics; and (4) clinical immunogenicity and efficacy data, typically in a single indication with extrapolation to other indications supported by mechanism of action and pharmacology data. The totality of evidence must demonstrate that the biosimilar is biosimilar to the reference product, meaning there are no clinically meaningful differences in safety, purity, or potency.
How do biosimilar prices compare to reference biologic prices in the U.S.?
Biosimilars typically launch at 15-30% discounts to reference biologic prices, with deeper discounts negotiated as competitive intensity increases and multiple biosimilars enter the market. However, U.S. biosimilar pricing is less predictable than in European markets due to the decentralized nature of payer negotiations. Actual discounts depend on payer contracts, formulary positioning, and competitive dynamics. For adalimumab, for example, biosimilar entry has driven reference product price reductions and biosimilar pricing competition, though the magnitude of discounts varies by payer and patient population.
What is interchangeability, and why is it important for biosimilar market penetration?
Interchangeability is an FDA designation that permits a pharmacist to substitute a biosimilar for the reference product without physician authorization, similar to generic drug substitution. To receive interchangeability status, a biosimilar sponsor must submit additional data demonstrating that the biosimilar can be expected to produce the same clinical result as the reference product in any given patient and that switching between the biosimilar and reference product (or among biosimilars) does not increase the risk of adverse events or diminish efficacy. Interchangeability is important because it facilitates automatic market capture through pharmacy-level substitution, accelerating biosimilar penetration and price competition. However, the FDA has granted interchangeability conservatively, limiting its current impact on market dynamics.
Which reference biologics are the primary targets for FDA biosimilar approvals?
The primary targets for FDA biosimilar approvals are high-value, widely prescribed reference biologics with substantial patient populations and significant commercial value. Key targets include adalimumab (Humira), used in autoimmune diseases; denosumab (Prolia/Xgeva), used in osteoporosis and cancer-related bone disease; ustekinumab (Stelara), used in psoriasis and inflammatory bowel disease; and various oncology-focused monoclonal antibodies used in solid tumors and hematologic malignancies. These reference products were selected by biosimilar manufacturers because they represent blockbuster markets with approaching or recently expired patent protections, creating commercial incentives for biosimilar development.
References
- U.S. Food and Drug Administration. Biosimilar Approvals Database. Accessed 2025. Summary of 76 total FDA-approved biosimilars through Q3 2025, including 18 approvals in 2024 and 18 in 2025 (through Q3), with reference to 5 approvals in 2023.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-29.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
